14
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Levodopa/carbidopa and entacapone in the treatment of Parkinson’s disease: efficacy, safety and patient preference

      1 , 2

      Patient preference and adherence

      Dove Medical Press

      levodopa, entacapone, Parkinson’s disease, preference, compliance, acceptance

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Levodopa (LD) is the oldest, most efficacious and best-tolerated drug for dopaminergic substitution of patients with Parkinson’s disease (PD). Its main drawback is its short half-life, which supports onset of motor complications in the long term. Therefore well-informed PD patients mostly accept LD therapy as late as possible. Recent LD trials indicate that a combination of LD with carbidopa (CD) and the catechol-O-methyltransferase (COMT) inhibitor entacapone (EN) may reduce the onset of these motor complications to a certain extent. This observation is further supported by pharmacokinetic trials and experimental research, but there is still a need to confirm this in a clinical trial, which is under way. Additionally, combined LD/CD/EN was superior to LD/CD administration regarding cognition, muscle behavior and gastrointestinal function in small clinical trials. Moreover there is accumulating evidence that combined COMT inhibition with LD administration reduces homocysteine synthesis. In the long term, homocysteine elevation supports onset of arteriosclerosis-related disorders, which are more frequent in PD patients according to epidemiological studies than in the normal healthy population. The introduction of LD/CD/EN in one tablet supported patients’ preference of COMT inhibition as an essential component of LD/DDI therapy, as this combination reduced number and size of tablets.

          Related collections

          Author and article information

          Journal
          Patient Prefer Adherence
          Patient preference and adherence
          Dove Medical Press
          1177-889X
          2009
          3 November 2009
          : 3
          : 51-59
          Affiliations
          [1 ]Department of Neurology, St. Joseph Hospital Berlin-Weißensee, Berlin, Germany;
          [2 ]IGSN, Ruhr University of Bochum, Bochum, Germany
          Author notes
          Correspondence: Thomas Müller, MD, Department of Neurology, St. Joseph Hospital Berlin-Weißensee, Gartenstr. 1, 13088 Berlin, Germany, Tel +49 30 92790223, Fax +49 30 92790703, Email th.mueller@ 123456alexius.de , thomas.mueller@ 123456ruhr-uni-bochum.de
          Article
          ppa-3-051
          2778405
          19936145
          © 2009 Müller, publisher and licensee Dove Medical Press Ltd.

          This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

          Categories
          Review

          Medicine

          acceptance, levodopa, preference, parkinson’s disease, entacapone, compliance

          Comments

          Comment on this article